Search
forLearn
5 / 801 resultslearn K&B
learn panthenyl ethyl ether
learn phenoxyethanol
learn plant sterol complex
Research
5 / 340 results
research Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin
Finasteride interacts with terazosin, but not doxazosin; caution needed.
research Minoxidil: a review of its pharmacological properties and therapeutic use.
Minoxidil effectively treats severe hypertension but may cause side effects, so careful monitoring is needed.
research Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
Food intake, not genetics, affects how the body processes tadalafil and finasteride.
research Advancements in Therapeutic Deep Eutectic Solvents as Multifunctional Transdermal Delivery Systems
TheDES improve drug delivery through the skin but need more safety checks.
research Recent Advances in the Use of Cubosomes as Drug Carriers with Special Emphasis on Topical Applications
Cubosomes improve drug delivery for skin and eye diseases by enhancing adhesion, retention, and release.
Community Join
5 / 1000+ resultscommunity 4 years on fin and totally stopped hair loss
A user stopped hair loss after taking finasteride daily for four years, with minimal regrowth and no side effects. They believe stress initially caused their hair loss.
community I cannot sleep anymore, what should I do
Finasteride may cause sleep disturbances, with some users experiencing insomnia. Reducing the dosage, switching brands, or trying Dutasteride might help.
community Minoxidil (3 months) & Finasteride (2 months) Update. 23M
The conversation is about a 23-year-old man's positive experience with hair regrowth using oral finasteride (1mg daily) and topical minoxidil (twice daily), with initial side effects including zero libido and watery semen that resolved except for the semen consistency. He also used dermarolling initially but stopped due to brittleness.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.